Neuroblastoma

Double Autologous Stem Cell Transplants Boost Survival in Neuroblastoma

Double Autologous Stem Cell Transplants Boost Survival in Neuroblastoma

Researchers achieved a 3-year event-free survival rate of 73.2% for tandem transplant patients.

FDA Approves First-Line Therapy for Neuroblastoma

FDA Approves First-Line Therapy for Neuroblastoma

By

The FDA fast-tracked the new drug for its safety and effectiveness in the treatment of a rare pediatric disorder.

Sign Up for Free e-newsletters



CME Focus